Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Current and Future Use of Artificial Intelligence in Electrocardiography

  • Martínez-Sellés D Oliveira Soares, Manuel
  • Marina-Breysse, Manuel
Artificial intelligence (AI) is increasingly used in electrocardiography (ECG) to assist in diagnosis, stratification, and management. AI algorithms can help clinicians in the following areas: (1) interpretation and detection of arrhythmias, ST-segment changes, QT prolongation, and other ECG abnormalities; (2) risk prediction integrated with or without clinical variables (to predict arrhythmias, sudden cardiac death, stroke, and other cardiovascular events); (3) monitoring ECG signals from cardiac implantable electronic devices and wearable devices in real time and alerting clinicians or patients when significant changes occur according to timing, duration, and situation; (4) signal processing, improving ECG quality and accuracy by removing noise/artifacts/interference, and extracting features not visible to the human eye (heart rate variability, beat-to-beat intervals, wavelet transforms, sample-level resolution, etc.); (5) therapy guidance, assisting in patient selection, optimizing treatments, improving symptom-to-treatment times, and cost effectiveness (earlier activation of code infarction in patients with ST-segment elevation, predicting the response to antiarrhythmic drugs or cardiac implantable devices therapies, reducing the risk of cardiac toxicity, etc.); (6) facilitating the integration of ECG data with other modalities (imaging, genomics, proteomics, biomarkers, etc.). In the future, AI is expected to play an increasingly important role in ECG diagnosis and management, as more data become available and more sophisticated algorithms are developed.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The G4 resolvase Dhx36 modulates cardiomyocyte differentiation and ventricular conduction system development

  • Gómez del Arco, Pablo
  • Muñoz Cánoves, Pura, 1962-
  • Redondo, Juan Miguel
Extensive genetic studies have elucidated cardiomyocyte differentiation and associated gene networks using single-cell RNA-seq, yet the intricate transcriptional mechanisms governing cardiac conduction system (CCS) development and working cardiomyocyte differentiation remain largely unexplored. Here we show that mice deleted for Dhx36 (encoding the Dhx36 helicase) in the embryonic or neonatal heart develop overt dilated cardiomyopathy, surface ECG alterations related to cardiac impulse propagation, and (in the embryonic heart) a lack of a ventricular conduction system (VCS). Heart snRNA-seq and snATAC-seq reveal the role of Dhx36 in CCS development and in the differentiation of working cardiomyocytes. Dhx36 deficiency directly influences cardiomyocyte gene networks by disrupting the resolution of promoter G-quadruplexes in key cardiac genes, impacting cardiomyocyte differentiation and CCS morphogenesis, and ultimately leading to dilated cardiomyopathy and atrioventricular block. These findings further identify crucial genes and pathways that regulate the development and function of the VCS/Purkinje fiber (PF) network., This work was supported by the Spanish Ministerio de Ciencia e Innovación (MICINN; grant RTI2018-096068), ERC-2016-AdG-741966, LaCaixa-HEALTH-HR17-00040, MDA, UPGRADE-H2020-825825, AFM, DPP-Spain, SGR, Fundació La MaratóTV3-80/19-202021, and MWRF; María-de-Maeztu Program for Units of Excellence to UPF (MDM-2014-0370) and the Severo-Ochoa Program for Centers of Excellence to CNIC (SEV-2015-0505) to P.M-C. The grants SAF2016-77816-P and PID2020-114773GB-I00 from MCIN/AEI/10.13039/501100011033 supported P.G-A. The grants PID2021-122388OB-100 from MCIN/AEI/10.13039/501100011033; and RED2024-154025-T; the Comunidad de Madrid and European Social Fund (ESF) grant AORTASANA-CM (B2017/BMD-3676); Fundació La Marató 2023 grant 202334-30-31; La Caixa Banking Foundation (project code HR18-00068); the MICINN – to JFN and JMR –; and the Instituto de Salud Carlos III (ISCIII) (CIBER-CVCB16/11/00264) supported JMR. The grants PID2022-104776RB-100 and CB16/11/00399 (CIBER CV) from MCIN/AEI/10.13039/501100011033, and La Caixa Research Health Foundation (Ref. HR23-00084) supported J.L.P. La Caixa Banking Foundation (HR18-00304); Severo Ochoa CNIC Intramural Project 12-2016 IGP; Fundació La MaratóTV3 (Ayudas a la investigación en enfermedades raras 2020: LAMARATO-2020); the ISCIII; and the European Commission (MAESTRIA H2020) supported J.J. The European Union Horizon 2020 research and innovation program under Grant Agreement#965286; the MCIN (grant#PID2019-109329RB-I00); Fondo Europeo de Desarrollo Regional (CB16/11/00458) and the Heart Rhythm Association of the Spanish Society of Cardiology supported DF. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation). The CBMSO is supported by Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid. CBMSO and CNIC are Severo Ochoa Centers of Excellence (grants CEX2021-001154-S and CEX2020-001041-S, respectively) funded by MCIN/AEI/10.13039/501100011033. FAS was supported by a Science and Innovation Fellowship (BES-2017-080629).
Repisalud
Publication Artículo científico (JournalArticle)

Kir2.1 dysfunction at the sarcolemma and the sarcoplasmic reticulum causes arrhythmias in a mouse model of Andersen–Tawil syndrome type 1

  • Macias, Alvaro
  • González-Guerra, Andrés
  • Moreno-Manuel, Ana I.
  • Cruz, Francisco M.
  • Gutiérrez, Lilian K.
  • García-Quintáns, Nieves
  • Roche-Molina, Marta
  • Bermúdez-Jiménez, Francisco
  • Andres, Vicente
  • Vera-Pedrosa, María Linarejos
  • Martínez-Carrascoso, Isabel
  • Bernal, Juan A.
  • Jalife, Jose
Repisalud
Publication Reseña (Review)

Current and Future Use of Artificial Intelligence in Electrocardiography.

  • Martínez-Sellés, Manuel
  • Marina-Breysse, Manuel
Artificial intelligence (AI) is increasingly used in electrocardiography (ECG) to assist in diagnosis, stratification, and management. AI algorithms can help clinicians in the following areas: (1) interpretation and detection of arrhythmias, ST-segment changes, QT prolongation, and other ECG abnormalities; (2) risk prediction integrated with or without clinical variables (to predict arrhythmias, sudden cardiac death, stroke, and other cardiovascular events); (3) monitoring ECG signals from cardiac implantable electronic devices and wearable devices in real time and alerting clinicians or patients when significant changes occur according to timing, duration, and situation; (4) signal processing, improving ECG quality and accuracy by removing noise/artifacts/interference, and extracting features not visible to the human eye (heart rate variability, beat-to-beat intervals, wavelet transforms, sample-level resolution, etc.); (5) therapy guidance, assisting in patient selection, optimizing treatments, improving symptom-to-treatment times, and cost effectiveness (earlier activation of code infarction in patients with ST-segment elevation, predicting the response to antiarrhythmic drugs or cardiac implantable devices therapies, reducing the risk of cardiac toxicity, etc.); (6) facilitating the integration of ECG data with other modalities (imaging, genomics, proteomics, biomarkers, etc.). In the future, AI is expected to play an increasingly important role in ECG diagnosis and management, as more data become available and more sophisticated algorithms are developed.
Repisalud
Publication Artículo científico (JournalArticle)

Practical approach for atrial cardiomyopathy characterization in patients with atrial fibrillation.

  • La Rosa, Giulio
  • Morillo, Carlos A
  • Quintanilla, Jorge G
  • Doltra, Adelina
  • Mont, Lluis
  • Rodríguez-Mañero, Moisés
  • Sarkozy, Andrea
  • Merino, José Luis
  • Vivas, David
  • Datino, Tomás
  • Calvo, David
  • Pérez-Castellano, Nicasio
  • Pérez-Villacastín, Julián
  • Fauchier, Laurent
  • Lip, Gregory
  • Hatem, Stéphane N
  • Jalife, José
  • Sanchis, Laura
  • Marín, Francisco
  • Filgueiras-Rama, David
Atrial fibrillation (AF) causes progressive structural and electrical changes in the atria that can be summarized within the general concept of atrial remodeling. In parallel, other clinical characteristics and comorbidities may also affect atrial tissue properties and make the atria susceptible to AF initiation and its long-term persistence. Overall, pathological atrial changes lead to atrial cardiomyopathy with important implications for rhythm control. Although there is general agreement on the role of the atrial substrate for successful rhythm control in AF, the current classification oversimplifies clinical management. The classification uses temporal criteria and does not establish a well-defined strategy to characterize the individual-specific degree of atrial cardiomyopathy. Better characterization of atrial cardiomyopathy may improve the decision-making process on the most appropriate therapeutic option. We review current scientific evidence and propose a practical characterization of the atrial substrate based on 3 evaluation steps starting with a clinical evaluation (step 1), then assess outpatient complementary data (step 2), and finally include information from advanced diagnostic tools (step 3). The information from each of the steps or a combination thereof can be used to classify AF patients in 4 stages of atrial cardiomyopathy, which we also use to estimate the success on effective rhythm control.
Repisalud
Publication Reseña (Review)

Promising tools for future drug discovery and development in antiarrhythmic therapy.

  • Mondéjar-Parreño, Gema
  • Sánchez-Pérez, Patricia
  • Cruz, Francisco Miguel
  • Jalife, José
Arrhythmia refers to irregularities in the rate and rhythm of the heart, with symptoms spanning from mild palpitations to life-threatening arrhythmias and sudden cardiac death. The complex molecular nature of arrhythmias complicates the selection of appropriate treatment. Current therapies involve the use of antiarrhythmic drugs (class I-IV) with limited efficacy and dangerous side effects and implantable pacemakers and cardioverter-defibrillators with hardware-related complications and inappropriate shocks. The number of novel antiarrhythmic drugs in the development pipeline has decreased substantially during the last decade and underscores uncertainties regarding future developments in this field. Consequently, arrhythmia treatment poses significant challenges, prompting the need for alternative approaches. Remarkably, innovative drug discovery and development technologies show promise in helping advance antiarrhythmic therapies. In this article, we review unique characteristics and the transformative potential of emerging technologies that offer unprecedented opportunities for transitioning from traditional antiarrhythmics to next-generation therapies. We assess stem cell technology, emphasizing the utility of innovative cell profiling using multiomics, high-throughput screening, and advanced computational modeling in developing treatments tailored precisely to individual genetic and physiological profiles. We offer insights into gene therapy, peptide, and peptibody approaches for drug delivery. We finally discuss potential strengths and weaknesses of such techniques in reducing adverse effects and enhancing overall treatment outcomes, leading to more effective, specific, and safer therapies. Altogether, this comprehensive overview introduces innovative avenues for personalized rhythm therapy, with particular emphasis on drug discovery, aiming to advance the arrhythmia treatment landscape and the prevention of sudden cardiac death. SIGNIFICANCE STATEMENT: Arrhythmias and sudden cardiac death account for 15%-20% of deaths worldwide. However, current antiarrhythmic therapies are ineffective and have dangerous side effects. Here, we review the field of arrhythmia treatment underscoring the slow progress in advancing the cardiac rhythm therapy pipeline and the uncertainties regarding evolution of this field. We provide information on how emerging technological and experimental tools can help accelerate progress and address the limitations of antiarrhythmic drug discovery.
Repisalud
Publication Artículo científico (JournalArticle)

Enhanced detection of atrial fibrillation in single-lead electrocardiograms using a Cloud-based artificial intelligence platform.

  • De Guio, François
  • Rienstra, Michiel
  • Lillo-Castellano, José María
  • Toribio-Fernández, Raquel
  • Lizcano, Carlos
  • Corrochano-Diego, Daniel
  • Jimenez-Virumbrales, David
  • Marina-Breysse, Manuel
BACKGROUND: Although smartphone-based devices have been developed to record 1-lead electrocardiogram (ECG), existing solutions for automatic detection of atrial fibrillation (AF) often has poor positive predictive value. OBJECTIVE: This study aimed to validate a Cloud-based deep-learning platform for automatic AF detection in a large cohort of patients using 1-lead ECG records. METHODS: We analyzed 8528 patients with 30-second ECG records from a single-lead handheld ECG device. Ground truth for AF presence was established through a benchmark algorithm and expert manual labeling. The Willem Artificial Intelligence (AI) platform, not trained on these ECGs, was used for automatic arrhythmia detection, including AF. A rules-based algorithm was also used for comparison. An expert cardiology committee reviewed false positives and negatives, and performance metrics were computed. RESULTS: The AI platform achieved an accuracy of 96.1% (initial labels) and 96.4% (expert review), with sensitivities of 83.3% and 84.2%, and specificities of 97.3% and 97.6%, respectively. The positive predictive value was 75.2% and 78.0%, and the negative predictive value was 98.4%. Performance of the AI platform largely exceeded the performance of the rules-based algorithm for all metrics. The AI also detected other arrhythmias, such as premature ventricular complexes, premature atrial complexes along with 1-degree atrioventricular blocks. CONCLUSION: The result of this external validation indicates that the AI platform can match cardiologist-level accuracy in AF detection from 1-lead ECGs. Such tools are promising for AF screening and have the potential to improve accuracy in noncardiology expert health care professional interpretation and trigger further tests for effective patient management.
Repisalud
Publication Artículo científico (JournalArticle)

The G4 resolvase Dhx36 modulates cardiomyocyte differentiation and ventricular conduction system development

  • Gomez-del Arco, Pablo
  • Isern, Joan
  • Jimenez-Carretero, Daniel
  • Lopez-Maderuelo, Dolores
  • Piñeiro-Sabarís, Rebeca
  • El Abdellaoui-Soussi, Fadoua
  • Torroja, Carlos
  • Vera-Pedrosa, María Linarejos
  • Grima-Terrén, Mercedes
  • Benguria, Alberto
  • Simón-Chica, Ana
  • Queiro-Palou, Antonio
  • Dopazo, Ana
  • Sanchez-Cabo, Fatima
  • Jalife, Jose
  • de la Pompa, Jose Luis
  • Filgueiras-Rama, David
  • Munoz-Canoves, Pura
  • Redondo, Juan Miguel
Extensive genetic studies have elucidated cardiomyocyte differentiation and associated gene networks using single-cell RNA-seq, yet the intricate transcriptional mechanisms governing cardiac conduction system (CCS) development and working cardiomyocyte differentiation remain largely unexplored. Here we show that mice deleted for Dhx36 (encoding the Dhx36 helicase) in the embryonic or neonatal heart develop overt dilated cardiomyopathy, surface ECG alterations related to cardiac impulse propagation, and (in the embryonic heart) a lack of a ventricular conduction system (VCS). Heart snRNA-seq and snATAC-seq reveal the role of Dhx36 in CCS development and in the differentiation of working cardiomyocytes. Dhx36 deficiency directly influences cardiomyocyte gene networks by disrupting the resolution of promoter G-quadruplexes in key cardiac genes, impacting cardiomyocyte differentiation and CCS morphogenesis, and ultimately leading to dilated cardiomyopathy and atrioventricular block. These findings further identify crucial genes and pathways that regulate the development and function of the VCS/Purkinje fiber (PF) network.
Repisalud
Publication Artículo científico (JournalArticle)

Molecular stratification of arrhythmogenic mechanisms in the Andersen Tawil Syndrome.

  • Manuel, Ana Isabel Moreno
  • Gutiérrez, Lilian K
  • Pedrosa, María Linarejos Vera
  • Uréndez, Francisco Miguel Cruz
  • Jiménez, Francisco José Bermúdez
  • Carrascoso, Isabel Martínez
  • Pérez, Patricia Sánchez
  • Macías, Álvaro
  • Jalife, Jose
Andersen Tawil Syndrome (ATS) is a rare inheritable disease associated with loss-of-function mutations in KCNJ2, the gene coding the strong inward rectifier potassium channel Kir2.1, which forms an essential membrane protein controlling cardiac excitability. ATS is usually marked by a triad of periodic paralysis, life-threatening cardiac arrhythmias and dysmorphic features, but its expression is variable and not all patients with a phenotype linked to ATS have a known genetic alteration. The mechanisms underlying this arrhythmogenic syndrome are poorly understood. Knowing such mechanisms would be essential to distinguish ATS from other channelopathies with overlapping phenotypes and to develop individualized therapies. For example, the recently suggested role of Kir2.1 as a countercurrent to sarcoplasmic calcium reuptake might explain the arrhythmogenic mechanisms of ATS and its overlap with catecholaminergic polymorphic ventricular tachycardia (CPVT). Here we summarize current knowledge on the mechanisms of arrhythmias leading to sudden cardiac death in ATS. We first provide an overview of the syndrome and its pathophysiology, from the patient´s bedside to the protein, and discuss the role of essential regulators and interactors that could play a role in cases of ATS. The review highlights novel ideas related to some post-translational channel interactions with partner proteins that might help define the molecular bases of the arrhythmia phenotype. We then propose a new all-embracing classification of the currently known ATS loss-of-function mutations according to their position in the Kir2.1 channel structure and their functional implications. We also discuss specific ATS pathogenic variants, their clinical manifestations and treatment stratification. The goal is to provide a deeper mechanistic understanding of the syndrome toward the development of novel targets and personalized treatment strategies.
Repisalud
Publication Artículo científico (JournalArticle)

Extracellular Kir2.1C122Y Mutant Upsets Kir2.1-PIP2 Bonds and Is Arrhythmogenic in Andersen-Tawil Syndrome.

  • Cruz, Francisco Miguel
  • Macias, Alvaro
  • Moreno-Manuel, Ana I
  • Gutiérrez, Lilian K
  • Vera-Pedrosa, María Linarejos
  • Martinez-Carrascoso, Isabel
  • Sánchez Pérez, Patricia
  • Ruiz Robles, Juan Manuel
  • Bermúdez-Jiménez, Francisco J
  • Díaz-Agustín, Aitor
  • Martínez de Benito, Fernando
  • Arias-Santiago, Salvador
  • Braza-Boils, Aitana
  • Martín-Martínez, Mercedes
  • Gutierrez-Rodríguez, Marta
  • Bernal, Juan Antonio
  • Zorio, Esther
  • Jiménez-Jaimez, Juan
  • Jalife, Jose
BACKGROUND Andersen-Tawil syndrome type 1 is a rare heritable disease caused by mutations in the gene coding the strong inwardly rectifying K+ channel Kir2.1. The extracellular Cys (cysteine)122-to-Cys154 disulfide bond in the channel structure is crucial for proper folding but has not been associated with correct channel function at the membrane. We evaluated whether a human mutation at the Cys122-to-Cys154 disulfide bridge leads to Kir2.1 channel dysfunction and arrhythmias by reorganizing the overall Kir2.1 channel structure and destabilizing its open state. METHODS We identified a Kir2.1 loss-of-function mutation (c.366 A>T; p.Cys122Tyr) in an ATS1 family. To investigate its pathophysiological implications, we generated an AAV9-mediated cardiac-specific mouse model expressing the Kir2.1C122Y variant. We employed a multidisciplinary approach, integrating patch clamping and intracardiac stimulation, molecular biology techniques, molecular dynamics, and bioluminescence resonance energy transfer experiments. RESULTS Kir2.1C122Y mice recapitulated the ECG features of ATS1 independently of sex, including corrected QT prolongation, conduction defects, and increased arrhythmia susceptibility. Isolated Kir2.1C122Y cardiomyocytes showed significantly reduced inwardly rectifier K+ (IK1) and inward Na+ (INa) current densities independently of normal trafficking. Molecular dynamics predicted that the C122Y mutation provoked a conformational change over the 2000-ns simulation, characterized by a greater loss of hydrogen bonds between Kir2.1 and phosphatidylinositol 4,5-bisphosphate than wild type (WT). Therefore, the phosphatidylinositol 4,5-bisphosphate-binding pocket was destabilized, resulting in a lower conductance state compared with WT. Accordingly, on inside-out patch clamping, the C122Y mutation significantly blunted Kir2.1 sensitivity to increasing phosphatidylinositol 4,5-bisphosphate concentrations. In addition, the Kir2.1C122Y mutation resulted in channelosome degradation, demonstrating temporal instability of both Kir2.1 and NaV1.5 proteins. CONCLUSIONS The extracellular Cys122-to-Cys154 disulfide bond in the tridimensional Kir2.1 channel structure is essential for the channel function. We demonstrate that breaking disulfide bonds in the extracellular domain disrupts phosphatidylinositol 4,5-bisphosphate-dependent regulation, leading to channel dysfunction and defects in Kir2.1 energetic stability. The mutation also alters functional expression of the NaV1.5 channel and ultimately leads to conduction disturbances and life-threatening arrhythmia characteristic of Andersen-Tawil syndrome type 1.
Repisalud
Publication Artículo científico (JournalArticle)

SNTA1 gene rescues ion channel function and is antiarrhythmic in cardiomyocytes derived from induced pluripotent stem cells from muscular dystrophy patients.

  • Jimenez-Vazquez, Eric N
  • Arad, Michael
  • Macías, Álvaro
  • Vera-Pedrosa, Maria L
  • Cruz, Francisco Miguel
  • Gutierrez, Lilian K
  • Cuttita, Ashley J
  • Monteiro da Rocha, André
  • Herron, Todd J
  • Ponce-Balbuena, Daniela
  • Guerrero-Serna, Guadalupe
  • Binah, Ofer
  • Michele, Daniel E
  • Jalife, Jose
Patients with cardiomyopathy of Duchenne Muscular Dystrophy (DMD) are at risk of developing life-threatening arrhythmias, but the mechanisms are unknown. We aimed to determine the role of ion channels controlling cardiac excitability in the mechanisms of arrhythmias in DMD patients. To test whether dystrophin mutations lead to defective cardiac NaV1.5-Kir2.1 channelosomes and arrhythmias, we generated iPSC-CMs from two hemizygous DMD males, a heterozygous female, and two unrelated control males. We conducted studies including confocal microscopy, protein expression analysis, patch-clamping, non-viral piggy-bac gene expression, optical mapping and contractility assays. Two patients had abnormal ECGs with frequent runs of ventricular tachycardia. iPSC-CMs from all DMD patients showed abnormal action potential profiles, slowed conduction velocities, and reduced sodium (INa) and inward rectifier potassium (IK1) currents. Membrane NaV1.5 and Kir2.1 protein levels were reduced in hemizygous DMD iPSC-CMs but not in heterozygous iPSC-CMs. Remarkably, transfecting just one component of the dystrophin protein complex (α1-syntrophin) in hemizygous iPSC-CMs from one patient restored channelosome function, INa and IK1 densities, and action potential profile in single cells. In addition, α1-syntrophin expression restored impulse conduction and contractility and prevented reentrant arrhythmias in hiPSC-CM monolayers. We provide the first demonstration that iPSC-CMs reprogrammed from skin fibroblasts of DMD patients with cardiomyopathy have a dysfunction of the NaV1.5-Kir2.1 channelosome, with consequent reduction of cardiac excitability and conduction. Altogether, iPSC-CMs from patients with DMD cardiomyopathy have a NaV1.5-Kir2.1 channelosome dysfunction, which can be rescued by the scaffolding protein α1-syntrophin to restore excitability and prevent arrhythmias. Supported by National Institutes of Health R01 HL122352 grant; 'la Caixa' Banking Foundation (HR18-00304); Fundación La Marató TV3: Ayudas a la investigación en enfermedades raras 2020 (LA MARATO-2020); Instituto de Salud Carlos III/FEDER/FSE; Horizon 2020 - Research and Innovation Framework Programme GA-965286 to JJ; the CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation), and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033). American Heart Association postdoctoral fellowship 19POST34380706s to JVEN. Israel Science Foundation to OB and MA [824/19]. Rappaport grant [01012020RI]; and Niedersachsen Foundation [ZN3452] to OB; US-Israel Binational Science Foundation (BSF) to OB and TH [2019039]; Dr. Bernard Lublin Donation to OB; and The Duchenne Parent Project Netherlands (DPPNL 2029771) to OB. National Institutes of Health R01 AR068428 to DM and US-Israel Binational Science Foundation Grant [2013032] to DM and OB.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference

  • Linz, Dominik
  • Andrade, Jason G.
  • Arbelo, Elena
  • Boriani, Giuseppe
  • Breithardt, Guenter
  • Camm, A. John
  • Caso, Valeria
  • Nielsen, Jens Cosedis
  • De Melis, Mirko
  • De Potter, Tom
  • Dichtl, Wolfgang
  • Diederichsen, Søren Zoega
  • Dobrev, Dobromir
  • Doll, Nicolas
  • Duncker, David
  • Dworatzek, Elke
  • Eckardt, Lars
  • Eisert, Christoph
  • Fabritz, Larissa
  • Farkowski, Michal
  • Filgueiras-Rama, David
  • Goette, Andreas
  • Guasch, Eduard
  • Hack, Guido
  • Hatem, Stéphane
  • Haeusler, Karl Georg
  • Healey, Jeff S.
  • Heidbuechel, Hein
  • Hijazi, Ziad
  • Hofmeister, Lucas H.
  • Hove-Madsen, Leif
  • Huebner, Thomas
  • Kääb, Stefan
  • Kotecha, Dipak
  • Malaczynska-Rajpold, Katarzyna
  • Merino, José Luis
  • Metzner, Andreas
  • Mont, Lluís
  • Ng, Ghulam Andre
  • Oeff, Michael
  • Parwani, Abdul Shokor
  • Puererfellner, Helmut
  • Ravens, Ursula
  • Rienstra, Michiel
  • Sanders, Prashanthan
  • Scherr, Daniel
  • Schnabel, Renate
  • Schotten, Ulrich
  • Sohns, Christian
  • Steinbeck, Gerhard
  • Steven, Daniel
  • Toennis, Tobias
  • Tzeis, Stylianos
  • van Gelder, Isabelle C.
  • van Leerdam, Roderick H.
  • Vernooy, Kevin
  • Wadhwa, Manish
  • Wakili, Reza
  • Willems, Stephan
  • Witt, Henning
  • Zeemering, Stef
  • Kirchhof, Paulus
Recent trial data demonstrate beneficial effects of active rhythm management in patients with atrial fibrillation (AF) and support the concept that a low arrhythmia burden is associated with a low risk of AF-related complications. The aim of this document is to summarize the key outcomes of the 9th AFNET/EHRA Consensus Conference of the Atrial Fibrillation NETwork (AFNET) and the European Heart Rhythm Association (EHRA)., The 9th AFNET/EHRA consensus conference was co-financed by AFNET, EHRA, and the MAESTRIA consortium (EU grant agreement ID: 965286). Industry participants paid an attendance fee for the conference and provided an industry perspective during the discussions at the meeting but had no involvement in the writing process., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lgi3-4 proteins modulate the KV1.5 channelosome and are potential therapeutic targets for atrial fibrillation

  • Socuéllamos, Paula G.
  • Macías, Álvaro
  • Benito-Bueno, Ángela de
  • Cruz, Francisco M.
  • Redondo-Moya, María
  • Coronado, María José
  • Ramil, Elvira
  • Rosado, Silvia
  • Rios-Rosado, Elsa Carolina
  • Valencia-Avezuela, María
  • Andrés-Delgado, Laura
  • Blázquez, José Antonio
  • Forteza-Gil, Alberto
  • Gutiérrez-Rodríguez, Marta
  • Jalife, José
  • Valenzuela, Carmen
We investigated the role of Lgi3-4 proteins in cardiac electrophysiology, with a specific focus on IKur, and their potential contribution to the pathophysiology of atrial fibrillation (AF)., Supported by Grants PID2019-104366RB-C21 (to C.V.), PID2019-104366RB-C22 (to M.G-R.), PID2022-137214OB-C21 (to C.V.); PID2022-137214OB-C22 (to M.G-R.) funded by MCIN/ AEI/10.13039/501100011033; Grant CB/11/00222 funded by Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (to C.V.); Grant S2022/BMD-7223 by Comunidad Autónoma de Madrid (CAM) (to C.V.); Grant FPU17/ 02731 (to P.G.S.); Grant BES-2017-080184 (to A.d.B.-B.); funded by Ministerio de Ciencia e Innovación. Supported also by National Heart, Lung and Blood Institute, NIH, grant number R01HL163943; La Caixa Banking Foundation project code HR18-00304 (LCF/PR/HR19/52160013); grants PI-FIS-2020 # PI20/01220 and PI-FIS-2023 # PI23/01039 from Instituto de Salud Carlos III (ISCIII) and co-funded by Fondo Europeo de Desarrollo Regional (FEDER), and by The European Union, respectively; grant PID2020-116935RB-I00 and BFU2016-75144-R funded by MCIN/AEI/10.13039/501100011033; Fundación La Marató de TV3 (736/C/2020) ‘amb el suport de la Fundació La Marató de TV3’; CIBERCV (CB16/11/00458; CB/11/00222 to CV); European Union’s Horizon 2020 grant agreement GA-965286; and Program S2022/BMD7229-CM ARCADIA-CM funded by Comunidad de Madrid (to JJ)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Genetic architecture of spatial electrical biomarkers for cardiac arrhythmia and relationship with cardiovascular disease

  • Young, W. J.
  • Haessler, J.
  • Benjamins, J. W.
  • Repetto, L.
  • Yao, J.
  • Isaacs, A.
  • Harper, A. R.
  • Ramirez, J.
  • Garnier, S.
  • van Duijvenboden, S.
  • Baldassari, A. R.
  • Pina Concas, M.
  • Duong, T.
  • Foco, L.
  • Isaksen, J. L.
  • Mei, H.
  • Noordam, R.
  • Nursyifa, C.
  • Richmond, A.
  • Santolalla, M. L.
  • Sitlani, C. M.
  • Soroush, N.
  • Thériault, S.
  • Trompet, S.
  • Aeschbacher, S.
  • Ahmadizar, F.
  • Alonso, A.
  • Brody, J. A.
  • Campbell, A.
  • Correa, A.
  • Darbar, D.
  • De Luca, A.
  • Deleuze, J. F.
  • Ellervik, C.
  • Fuchsberger, C.
  • Goel, A.
  • Grace, C.
  • Guo, X.
  • Hansen, T.
  • Heckbert, S. R.
  • Jackson, R. D.
  • Kors, J. A.
  • Lima-Costa, M. F.
  • Linneberg, A.
  • Macfarlane, P. W.
  • Morrison, A. C.
  • Navarro, P.
  • Porteous, D. J.
  • Pramstaller, P. P.
  • Reiner, A. P.
  • Risch, L.
  • Schotten, U.
  • Shen, X.
  • Sinagra, G.
  • Soliman, E. Z.
  • Stoll, M.
  • Tarazona-Santos, E.
  • Tinker, A.
  • Trajanoska, K.
  • Villard, E.
  • Warren, H. R.
  • Whitsel, E. A.
  • Wiggins, K. L.
  • Arking, D. E.
  • Avery, C. L.
  • Conen, D.
  • Girotto, G.
  • Grarup, N.
  • Hayward, C.
  • Jukema, J. W.
  • Mook-Kanamori, D. O.
  • Olesen, M. S.
  • Padmanabhan, S.
  • Psaty, B. M.
  • Pattaro, C.
  • Ribeiro, A. L. P.
  • Rotter, J. I.
  • Stricker, B. H.
  • van der Harst, P.
  • van Duijn, C. M.
  • Verweij, N.
  • Wilson, J. G.
  • Orini, M.
  • Charron, P.
  • Watkins, H.
  • Kooperberg, C.
  • Lin, H. J.
  • Wilson, J. F.
  • Kanters, J. K.
  • Sotoodehnia, N.
  • Mifsud, B.
  • Lambiase, P. D.
  • Tereshchenko, L. G.
  • Munroe, P. B.
The 3-dimensional spatial and 2-dimensional frontal QRS-T angles are measures derived from the vectorcardiogram. They are independent risk predictors for arrhythmia, but the underlying biology is unknown. Using multi-ancestry genome-wide association studies we identify 61 (58 previously unreported) loci for the spatial QRS-T angle (N = 118,780) and 11 for the frontal QRS-T angle (N = 159,715). Seven out of the 61 spatial QRS-T angle loci have not been reported for other electrocardiographic measures. Enrichments are observed in pathways related to cardiac and vascular development, muscle contraction, and hypertrophy. Pairwise genome-wide association studies with classical ECG traits identify shared genetic influences with PR interval and QRS duration. Phenome-wide scanning indicate associations with atrial fibrillation, atrioventricular block and arterial embolism and genetically determined QRS-T angle measures are associated with fascicular and bundle branch block (and also atrioventricular block for the frontal QRS-T angle). We identify potential biology involved in the QRS-T angle and their genetic relationships with cardiovascular traits and diseases, may inform future research and risk prediction.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The G4 resolvase Dhx36 modulates cardiomyocyte differentiation and ventricular conduction system development

  • Gómez del Arco, Pablo
  • Muñoz Cánoves, Pura, 1962-
  • Redondo, Juan Miguel
Extensive genetic studies have elucidated cardiomyocyte differentiation and associated gene networks using single-cell RNA-seq, yet the intricate transcriptional mechanisms governing cardiac conduction system (CCS) development and working cardiomyocyte differentiation remain largely unexplored. Here we show that mice deleted for Dhx36 (encoding the Dhx36 helicase) in the embryonic or neonatal heart develop overt dilated cardiomyopathy, surface ECG alterations related to cardiac impulse propagation, and (in the embryonic heart) a lack of a ventricular conduction system (VCS). Heart snRNA-seq and snATAC-seq reveal the role of Dhx36 in CCS development and in the differentiation of working cardiomyocytes. Dhx36 deficiency directly influences cardiomyocyte gene networks by disrupting the resolution of promoter G-quadruplexes in key cardiac genes, impacting cardiomyocyte differentiation and CCS morphogenesis, and ultimately leading to dilated cardiomyopathy and atrioventricular block. These findings further identify crucial genes and pathways that regulate the development and function of the VCS/Purkinje fiber (PF) network., This work was supported by the Spanish Ministerio de Ciencia e Innovación (MICINN; grant RTI2018-096068), ERC-2016-AdG-741966, LaCaixa-HEALTH-HR17-00040, MDA, UPGRADE-H2020-825825, AFM, DPP-Spain, SGR, Fundació La MaratóTV3-80/19-202021, and MWRF; María-de-Maeztu Program for Units of Excellence to UPF (MDM-2014-0370) and the Severo-Ochoa Program for Centers of Excellence to CNIC (SEV-2015-0505) to P.M-C. The grants SAF2016-77816-P and PID2020-114773GB-I00 from MCIN/AEI/10.13039/501100011033 supported P.G-A. The grants PID2021-122388OB-100 from MCIN/AEI/10.13039/501100011033; and RED2024-154025-T; the Comunidad de Madrid and European Social Fund (ESF) grant AORTASANA-CM (B2017/BMD-3676); Fundació La Marató 2023 grant 202334-30-31; La Caixa Banking Foundation (project code HR18-00068); the MICINN – to JFN and JMR –; and the Instituto de Salud Carlos III (ISCIII) (CIBER-CVCB16/11/00264) supported JMR. The grants PID2022-104776RB-100 and CB16/11/00399 (CIBER CV) from MCIN/AEI/10.13039/501100011033, and La Caixa Research Health Foundation (Ref. HR23-00084) supported J.L.P. La Caixa Banking Foundation (HR18-00304); Severo Ochoa CNIC Intramural Project 12-2016 IGP; Fundació La MaratóTV3 (Ayudas a la investigación en enfermedades raras 2020: LAMARATO-2020); the ISCIII; and the European Commission (MAESTRIA H2020) supported J.J. The European Union Horizon 2020 research and innovation program under Grant Agreement#965286; the MCIN (grant#PID2019-109329RB-I00); Fondo Europeo de Desarrollo Regional (CB16/11/00458) and the Heart Rhythm Association of the Spanish Society of Cardiology supported DF. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation). The CBMSO is supported by Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid. CBMSO and CNIC are Severo Ochoa Centers of Excellence (grants CEX2021-001154-S and CEX2020-001041-S, respectively) funded by MCIN/AEI/10.13039/501100011033. FAS was supported by a Science and Innovation Fellowship (BES-2017-080629).
Archivo Digital UPM
Publication Artículo científico (JournalArticle)

Smart-IoT Business Process Management: A Case Study on Remote Digital Early Cardiac Arrhythmia Detection and Diagnosis

  • Gómez Valiente, Patricia|||0009-0000-7221-6079
  • Pérez Benedí, Jennifer|||0000-0003-3192-7995
  • Lillo-Castellano, José María|||0000-0001-7215-4314
  • Marina-Breysse, Manuel|||0000-0002-2047-1868